乳腺癌免疫治疗的最新进展
|
摘要
虽然恶性肿瘤已进入免疫治疗时代,但乳腺癌的免疫治疗却举步维艰。2018年底Ⅲ期IMpassion 130研究在欧洲肿瘤内科学会(ESMO)年会上的发表,标志着乳腺癌免疫治疗时代的开始。目前,乳腺癌的免疫治疗研究主要集中在疫苗、嵌合抗原受体T细胞(CAR-T)治疗和免疫检查点抑制剂(ICIs)等方面。合理选择人群和治疗模式,是未来乳腺癌免疫治疗领域的重点发展方向。
Although malignant tumors have entered into the era of immunotherapy,immunotherapy for breast cancer has been difficult. With the publication of the Phase Ⅲ IMpassion 130 study at the end of 2018 at the Eurapean Society of Medical Oncology( ESMO) annual meeting,the immune era of breast cancer has begun At present,immunotherapy research on breast cancer mainly focuses on vaccines,chimeric antigen receptor-engineered T cells( CAR-T) treatment and immune checkpoint inhibitors( ICIs). How to reasonably select the population and treatment mode is the key development direction in the field of breast cancer immunotherapy in the future.
Although malignant tumors have entered into the era of immunotherapy,immunotherapy for breast cancer has been difficult. With the publication of the Phase Ⅲ IMpassion 130 study at the end of 2018 at the Eurapean Society of Medical Oncology( ESMO) annual meeting,the immune era of breast cancer has begun At present,immunotherapy research on breast cancer mainly focuses on vaccines,chimeric antigen receptor-engineered T cells( CAR-T) treatment and immune checkpoint inhibitors( ICIs). How to reasonably select the population and treatment mode is the key development direction in the field of breast cancer immunotherapy in the future.
引文
[1]ALEXANDROV L B,NIK-ZAINAL S,WEDGE D C,et al.Signatures of mutational processes in human cancer[J].Nature,2013,500(7463):415-421.
[2]YARCHOAN M,HOPKINS A,JAFFEE E M.Tumor mutational burden and response rate to PD-1 inhibition[J].N Engl J Med,2017,377(25):2500-2501.
[3]BANERJI S,CIBULSKIS K,RANGEL-ESCARENO C,et al.Sequence analysis of mutations and translocations across breast cancer subtypes[J].Nature,2012,486(7403):405-409.
[4]MITTENDORF E A,PHILIPS A V,MERIC-BERNSTAMF,et al.PD-L1 expression in triple-negative breast cancer[J].Cancer Immunol Res,2014,2(4):361-370.
[5]WIMBERLY H,BROWN J R,SCHALPER K,et al.PD-L1expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer[J].Cancer Immunol Res,2015,3(4):326-332.
[6]ZHANG M,SUN H,ZHAO S,et al.Expression of PD-L1and prognosis in breast cancer:a meta-analysis[J].Oncotarget,2017,8(19):31347-31354.
[7]LOI S,SIRTAINE N,PIETTE F,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phaseⅢrandomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.
[8]LOI S,MICHIELS S,SALGADO R,et al.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the Fin HER trial[J].Ann Oncol,2014,25(8):1544-1550.
[9]BECKERS R K,SELINGER C I,VILAIN R,et al.Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome[J].Histopathology,2016,69(1):25-34.
[10]ALLAHVERDIYEV A,TARI G,BAGIROVA M,et al.Current approaches in development of immunotherapeutic vaccines for breast cancer[J].J Breast Cancer,2018,21(4):343-353.
[11]PARVIZPOUR S,RAZMARA J,OMIDI Y.Breast cancer vaccination comes to age:impacts of bioinformatics[J].Bioimpacts,2018,8(3):223-235.
[12]WANG J,ZHOU P.New approaches in CAR-T cell immunotherapy for breast cancer[J].Adv Exp Med Biol,2017,1026:371-381.
[13]SCHMID P,ADAMS S,RUGO H S,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
[14]ADAMS S,SCHMID P,RUGO H S,et al.Phase 2 study of Pembrolizumab(Pembro)monotherapy for previously treatedmetastatic triple-negative breast cancer(m TNBC):KEYNOTE-086 cohort A[J].J Clin Oncol,2017,35(15s):1008.
[15]ADAMS S,LOI S,TOPPMEYER D,et al.Phase 2 study of Pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer(m TNBC):preliminarydata from KEYNOTE-086 cohort B[J].J Clin Oncol,2017,35(15s):1088.
[16]VINAYAK S,TOLANEY S,SCHWARTZBERG L,et al.TOPACIO/Keynote-162:Niraparib+pembrolizumab in patients with metastatic triple-negative breast cancer(TNBC).a phase 2 trial[J].J Clin Oncol,2018,36(Suppl):1011.
[17]BU X,YAO Y,LI X.Immune checkpoint blockade in breast cancer therapy[J].Adv Exp Med Biol,2017,1026:383-402.
[2]YARCHOAN M,HOPKINS A,JAFFEE E M.Tumor mutational burden and response rate to PD-1 inhibition[J].N Engl J Med,2017,377(25):2500-2501.
[3]BANERJI S,CIBULSKIS K,RANGEL-ESCARENO C,et al.Sequence analysis of mutations and translocations across breast cancer subtypes[J].Nature,2012,486(7403):405-409.
[4]MITTENDORF E A,PHILIPS A V,MERIC-BERNSTAMF,et al.PD-L1 expression in triple-negative breast cancer[J].Cancer Immunol Res,2014,2(4):361-370.
[5]WIMBERLY H,BROWN J R,SCHALPER K,et al.PD-L1expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer[J].Cancer Immunol Res,2015,3(4):326-332.
[6]ZHANG M,SUN H,ZHAO S,et al.Expression of PD-L1and prognosis in breast cancer:a meta-analysis[J].Oncotarget,2017,8(19):31347-31354.
[7]LOI S,SIRTAINE N,PIETTE F,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phaseⅢrandomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.
[8]LOI S,MICHIELS S,SALGADO R,et al.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the Fin HER trial[J].Ann Oncol,2014,25(8):1544-1550.
[9]BECKERS R K,SELINGER C I,VILAIN R,et al.Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome[J].Histopathology,2016,69(1):25-34.
[10]ALLAHVERDIYEV A,TARI G,BAGIROVA M,et al.Current approaches in development of immunotherapeutic vaccines for breast cancer[J].J Breast Cancer,2018,21(4):343-353.
[11]PARVIZPOUR S,RAZMARA J,OMIDI Y.Breast cancer vaccination comes to age:impacts of bioinformatics[J].Bioimpacts,2018,8(3):223-235.
[12]WANG J,ZHOU P.New approaches in CAR-T cell immunotherapy for breast cancer[J].Adv Exp Med Biol,2017,1026:371-381.
[13]SCHMID P,ADAMS S,RUGO H S,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
[14]ADAMS S,SCHMID P,RUGO H S,et al.Phase 2 study of Pembrolizumab(Pembro)monotherapy for previously treatedmetastatic triple-negative breast cancer(m TNBC):KEYNOTE-086 cohort A[J].J Clin Oncol,2017,35(15s):1008.
[15]ADAMS S,LOI S,TOPPMEYER D,et al.Phase 2 study of Pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer(m TNBC):preliminarydata from KEYNOTE-086 cohort B[J].J Clin Oncol,2017,35(15s):1088.
[16]VINAYAK S,TOLANEY S,SCHWARTZBERG L,et al.TOPACIO/Keynote-162:Niraparib+pembrolizumab in patients with metastatic triple-negative breast cancer(TNBC).a phase 2 trial[J].J Clin Oncol,2018,36(Suppl):1011.
[17]BU X,YAO Y,LI X.Immune checkpoint blockade in breast cancer therapy[J].Adv Exp Med Biol,2017,1026:383-402.